Author:
Pandit Neha Sheth,Chastain Daniel B.,Pallotta Andrea M.,Badowski Melissa E.,Huesgen Emily C.,Michienzi Sarah M.
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. • Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at
http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultsandAdolescentGL.pdf
. Access on July 12, 2019. Standard of care guidelines that discuss the role of ART in treatment experienced patients.
2. Lee S, Kim S, Chang H, Jung H, Kim Y, Hwang S, et al. Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus. Infect Chemother. 2018;50:252–62.
https://doi.org/10.3947/ic.2018.50.3.252
.
3. Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60:7086–97.
4. Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentere, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e347–56.
https://doi.org/10.1016/S2352-3018(18)30091-2
.
5. Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, Lopez-Cortes L, et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentere, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e357–65.
https://doi.org/10.1016/S2352-3018(18)30092-4
.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献